EUVIMEDEUVIMED entdecken
Open Access · CC0

Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States

Haider J Warraich iD, Hasan K Siddiqi, Diane G Li, Jeroen van Meijgaard, Muthiah Vaduganathan

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0294164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Haider J Warraich und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States of America. Hauptthemen laut MEDLINE: Pharmacies, Pharmacy, Diabetes Mellitus, Insulins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes medications place significant financial burden on patients but less is known about factors affecting cost variation.

Objective

To examine pharmacy and neighborhood factors associated with cost variation for diabetes drugs in the US. Research design, subjects and measures We used all-payer US pharmacy data from 45,874 chain and independent pharmacies reflecting 7,073,909 deidentified claims. We divided diabetes drugs into insulins, non-insulin generic medications, and brand name medications. Generalized linear models, stratified by pharmacy type, identified pharmacy and neighborhood factors associated with higher or lower cash price-per-unit (PPU) for each set of drugs.

Results

Cash PPU was highest for brand name therapies ($149.4±203.2), followed by insulins ($42.4±25.0), and generic therapies ($1.3±4.4). Pharmacy-level price variation was greater for non-insulin generic therapies than insulins or brand name therapies. Chain pharmacies had both lower prices and lesser variation compared with independent pharmacies.

Conclusions

Cash prices for diabetes medications in the US can vary considerably and that the greatest degree of price variation occurs in non-insulin generic therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmaciesPharmacyDiabetes MellitusInsulinsHumansUnited StatesDrug CostsDrugs, GenericHypoglycemic Agents

Substanzen

Drugs, GenericHypoglycemic AgentsInsulins

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States of America.
  • Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States of America.
  • GoodRx Inc, Santa Monica, CA, United States of America.

ORCID-Profile: Haider J Warraich

Zitieren

APA

Warraich, H. J., Siddiqi, H. K., Li, D. G., van Meijgaard, J., & Vaduganathan, M. (2023). Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States. PLOS ONE. https://doi.org/10.1371/journal.pone.0294164

Vancouver

Warraich HJ, Siddiqi HK, Li DG, van Meijgaard J, Vaduganathan M. Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States. PLOS ONE. 2023. doi:10.1371/journal.pone.0294164

BibTeX
@article{Warraich2023,
  author = {Warraich, Haider J and Siddiqi, Hasan K and Li, Diane G and van Meijgaard, Jeroen and Vaduganathan, Muthiah},
  title = {Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0294164}
}
Kostenlos starten →